Novimmune Announces Presentations at 2015 American College

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Novimmune Announces Presentations at 2015 American College of Rheumatology (ACR) Annual Meeting

GENEVA, SWITZERLAND--(Marketwired - Nov 2, 2015) - Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders and cancer, today announced plans for several presentations at the upcoming 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, California on November 6-11. The Company will present four abstracts on Novimmune's NI-0501, which targets interferon-gamma IFNγ and is the first treatment developed specifically for Hemophagocytic Lymphohistiocytosis (HLH). The secondary form of HLH can be associated with inflammatory/autoimmune conditions. Novimmune is also presenting a poster on NI-0101, which targets Toll-like receptor 4.

"Discovering a safe and effective treatment for Hemophagocytic Lymphohistiocytosis, or HLH, is a core focus for us at Novimmune, so we are proud that four abstracts will be presented at ACR relating to our new drug, NI-0501, the first treatment specifically developed for HLH," said Novimmune Chief Executive Officer Jack Barbut. "We currently are testing NI-0501 as a first-line treatment for HLH at five investigational sites in the US and 14 sites in five European countries. In addition, a poster at ACR relates to translational data and phase 1 study results for NI-0101, our treatment for Rheumatoid Arthritis. We remain committed to further developing new and existing therapies to provide treatment options for patients dealing with devastating diseases like HLH and painful, debilitating autoimmune and inflammatory diseases."

Oral and poster abstract presentations on hemophagocytic lymphohistiocytosis (HLH) are as follows:

(1)   Abstract Number: 3076

Interferon Gamma (IFNg) is the Driving Mediator of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) in TLR9-Mediated Pathogenesis in Mice and is Correlated to Disease Parameters in Children

Cristina de Min 1 , Vanessa Buatois 1 , Laurence Chatel 1 , Laura Cons 2 , Francoise Richard 3 , Claudia Bracaglia 4 , Fabrizio De Benedetti Sr. 5 , Marie Kosco-Vilbois 1 and Walter Ferlin 1 , 1 Novimmune S.A., Geneva, Switzerland, 2 Novimmune S.A., Plan-Les-Ouates, Geneva, Switzerland, 3 Novimmune SA, Geneva, Switzerland, 4 Pediatric Medicine, Division of Rheumatology, Rome, Italy, 5 Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.

Session Information Date: Tuesday, November 10, 2015 Session Title: ACR Plenary Session III: Discovery 2015 Session Type: ACR Plenary Session Session Time : 11:00AM-12:30PM

(2) Abstract Number: 2433

Anti Interferon-Gamma (IFNg) Monoclonal Antibody Treatment in a Child with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)

Claudia Bracaglia 1 , Giusi Prencipe 1 , Antonio Gatto 2 , Manuela Pardeo 1 , Geneviève Lapeyre 3 , Luigi Raganelli 1 , Emiliano Marasco 2 , Antonella Insalaco 2 , Walter Ferlin 3 , Robert Nelson 3 , Cristina de Min 3 and Fabrizio De Benedetti Sr. 1 , 1 Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 2 Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 3 Novimmune S.A., Geneva, Switzerland.

Session Information Date: Tuesday, November 10, 2015 Session Title : Pediatric Rheumatology-Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions Session Type: ACR Poster Session C Session Time : 9:00AM-11:00AM

(3) Abstract Number: 3096

Interferon-Gamma (IFNg) in Macrophage Activation Syndrome (MAS): CXCL9 Levels as a Biomarker for IFNg Production in MAS

Claudia Bracaglia 1 , Denise Pires Marafon 2 , Ivan Caiello 1 , Kathy De Graaf 3 , Florence Guilhot 4 , Walter Ferlin 4 , Sergio Davì 5 , Grant Schulert 6 , Angelo Ravelli 5 , Alexei A. Grom 7 , Robert Nelson 4 , Cristina de Min 4 and Fabrizio De Benedetti Sr. 1 , 1 Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 2 Pediatric Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 3 Novimmune S.A., Geneva, Switzerland, 4 Novimmune S.A., Geneva, Switzerland, 5 Istituto Giannina Gaslini and University of Genova, Genova, Italy, 6 Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7 Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Session Information Date: Tuesday, November 10, 2015 Session Title : Pediatric Rheumatology-Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions Session Type: ACR Concurrent Abstract Session Session Time : 2:30PM- 4:00PM

(4) Abstract Number: 3097

Innovative Approach for the Identification of an Appropriate Dose Regimen of a Targeted Treatment, NI-0501, an Anti-Interferon Gamma (IFNg) Antibody, in Patients with Hemophagocytic Lymphohistiocytosis (HLH)

Cristina de Min 1 , Philippe Jacqmin 2 , Christian Laveille 3 , Robert Nelson 1 , Florence Guilhot 1 , Maureen Deehan 1 , Marie Kosco-Vilbois 1 , Walter Ferlin 1 and Genevieve Lapeyre 1 , 1 Novimmune S.A., Geneva, Switzerland, 2 SGS Exprimo, Mechelen, Belgium, 3 SGS Exprimo NV, Mechelen, Belgium

Session Information Date: Tuesday, November 10, 2015 Session Title : Pediatric Rheumatology-Clinical and Therapeutic Aspects III: Miscellaneous Pediatric Rheumatic Diseases Session Type: ACR Concurrent Abstract Session Session Time : 2:30PM- 4:00PM

(5) Abstract Number: 1661

Translational Data and Phase 1 Study Results of a New Monoclonal Antibody Targeting Toll like Receptor 4 (TLR4) Developed for Rheumatoid Arthritis (RA) Treatment with a Potential for Personalized Medicine

Emmanuel Monnet 1 , Limin Shang 1 , Geneviève Lapeyre 1 , Kathy De Graaf 2 , Eric Hatterer 1 , Gaelle Wambiekele 1 , Walter Ferlin 1 , Philippe Jacqmin 3 , Cem Gabay 4 , Jeremy Sokolove 5 , Simon Jones 6 , Ernest H. Choy 7 , Iain B. McInnes 8 , Marie Kosco-Vilbois 1 and Cristina de Min 1 , 1 Novimmune S.A., Geneva, Switzerland, 2 Novimmune S.A., Geneva, Switzerland, 3 SGS Exprimo, Mechelen, Belgium, 4 Rheumatology, Geneva University Hospital, Geneva, Switzerland, 5 Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 6 Cardiff Institute of Infection & Immunity, Cardiff, United Kingdom, 7 Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, 8 Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

Session Information Date: Monday, November 9, 2015 Session Title : Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy Poster II Session Type: ACR Poster Session B Session Time : 9:00AM-11:00AM

About ACR

The American College of Rheumatology (ACR) is an ethically-driven, professional membership organization committed to improving the care of patients with rheumatic disease and advancing the rheumatology subspecialty. Founded in 1934, ACR is a not-for-profit, global medical society that serves over 9,500 physicians, health professionals and scientists worldwide.

About Hemophagocytic Lymphohistiocytosis (HLH)

HLH is a severe immune system disorder caused by an overactive and poorly controlled T cell function that triggers aberrant activation of the immune system. The disease typically arises in pediatric patients and is lethal if untreated. Even with the current best available care, HLH has a high rate of mortality.

Novimmune is currently testing a new drug, NI-0501, as a first-line and second-line treatment for HLH. The drug is the first treatment specifically developed for HLH. NI-0501 is a fully human monoclonal antibody that neutralizes interferon gamma, a cell-signaling protein believed to play a pivotal role in the development of HLH. In the ongoing phase II study, NI-0501 was initially administered to patients showing unsatisfactory response or intolerance to conventional therapies including chemotherapy, immune-suppressive medicines, and immune-depleting drugs. The recently approved amendment to the protocol allows NI-0501 to be administered to patients as a first-line treatment before any other intervention.

The study is currently underway at five investigational sites in the US and 14 sites in five European countries.

About Novimmune

Novimmune SA is a Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva. More information is available on the company website at www.novimmune.com .

Contact: Jack Barbut +41 22 839 71 41 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 261

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 125

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 191

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 210

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 191

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 99

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 161

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 211

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Marqeta Class Action Lawsuit: Investor Rights Alert

Updated Category News Views 115

Investors Take Action: Marqeta, Inc. Securities Lawsuit In an important update for shareholders of Marqeta, Inc. (NASDAQ: MQ), it has been brought to attention by Kahn Swick & Foti, LLC that investors who have incurred losses exceeding $100,000 have until a specific deadline to file lead plaintiff applications in a key class action lawsuit. Understanding the Class Action...

Continue Reading
Emerging Strategies for the Chronic Refractory Cough Market

Updated Category News Views 266

Chronic Refractory Cough Market Overview The chronic refractory cough market is emerging as a significant opportunity for pharmaceutical companies. As analyzed, the market size is poised for considerable growth due to various factors, including rising disease prevalence and a corresponding increase in approved product availability. Notably, several innovative therapies...

Continue Reading
Hydreight Technologies: A Rising Star in Healthcare Services

Updated Category News Views 185

Hydreight Technologies Achieves Major Recognition In the fast-paced world of technology and healthcare, Hydreight Technologies Inc. has made an impressive mark, securing the spot of No. 77 on a prestigious list of the fastest-growing companies in North America. This ranking, part of the 2025 Deloitte Technology Fast 500™, positions Hydreight among elite innovators and...

Continue Reading
Empowering Communities: PHFA's $75 Million Housing RFP Launch

Updated Category News Views 90

Introducing the New PHARE Funding Opportunities for Housing The Pennsylvania Housing Finance Agency (PHFA) is excited to announce a new funding opportunity that aims to improve housing availability and affordability across the state. This initiative encourages organizations to submit proposals for projects designed to address urgent housing challenges in their...

Continue Reading
Investigating Investor Claims Against Polestar Automotive

Updated Category News Views 114

Investigation of Investor Claims Against Polestar Automotive Faruqi & Faruqi, LLP, a prominent national securities law firm, is initiating an investigation into potential claims for investors of Polestar Automotive Holding UK PLC. If you've experienced financial losses linked to Polestar, now is the time to explore your options and safeguard your rights. Understanding...

Continue Reading